Medpace Stock Forecast, Price & News

Medpace (NASDAQ:MEDP) Frequently Asked Questions

Is Medpace a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace or view top-rated stocks.

How has Medpace's stock been impacted by Coronavirus?

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MEDP stock has increased by 97.0% and is now trading at $164.78.
View which stocks have been most impacted by COVID-19.

Are investors shorting Medpace?

Medpace saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 766,500 shares, an increase of 25.6% from the November 30th total of 610,100 shares. Based on an average trading volume of 168,300 shares, the short-interest ratio is presently 4.6 days. Currently, 2.6% of the shares of the stock are sold short.
View Medpace's Short Interest.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for Medpace.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Tuesday, February 15th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "9164466".

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) posted its earnings results on Sunday, October, 24th. The company reported $1.29 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.07 by $0.22. The business had revenue of $295.57 million for the quarter, compared to the consensus estimate of $291.55 million. Medpace had a trailing twelve-month return on equity of 21.71% and a net margin of 16.71%. The business's revenue was up 28.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.13 EPS.
View Medpace's earnings history.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2021 earnings guidance on Monday, November, 1st. The company provided EPS guidance of $4.660-$4.770 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.450. The company issued revenue guidance of $1.14 billion-$1.15 billion, compared to the consensus revenue estimate of $1.14 billion.

What price target have analysts set for MEDP?

2 equities research analysts have issued twelve-month price objectives for Medpace's shares. Their forecasts range from $167.90 to $205.00. On average, they anticipate Medpace's share price to reach $186.45 in the next year. This suggests a possible upside of 13.2% from the stock's current price.
View analysts' price targets for Medpace or view top-rated stocks among Wall Street analysts.

Who are Medpace's key executives?

Medpace's management team includes the following people:

• August James Troendle, Chairman & Chief Executive Officer
• Jesse J. Geiger, President (LinkedIn Profile)
• Susan E. Burwig, Executive Vice President-Operations (LinkedIn Profile)
• Kevin M. Brady, Chief Financial Officer & Treasurer
• Daniel O’Leary, Senior Vice President-Medical Department

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medpace's key competitors?

Some companies that are related to Medpace include Bitcoin Group (BTGGF), Incyte (INCY), Charles River Laboratories International (CRL), ICON Public (ICLR), Exact Sciences (EXAS), Syneos Health (SYNH), SomaLogic (SLGC), National Research (NRC), Science 37 (SNCE), Anavex Life Sciences (AVXL), Absci (ABSI), Zymergen (ZY), Inotiv (NOTV), Starpharma (SPHRY) and Luna Innovations (LUNA).
View all of MEDP's competitors.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a number of retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (1.36%), Riverbridge Partners LLC (0.85%), Russell Investments Group Ltd. (0.38%), Scout Investments Inc. (0.24%), Nordea Investment Management AB (0.20%) and McGuire Investment Group LLC (0.17%). Company insiders that own Medpace stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends for Medpace.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Boston Trust Walden Corp, Scout Investments Inc., Crossmark Global Holdings Inc., Exchange Traded Concepts LLC, McGuire Investment Group LLC, Dixon Hubard Feinour & Brown Inc. VA, and Nordea Investment Management AB. Company insiders that have sold Medpace company stock in the last year include Ashley M Keating, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Stephen P Ewald, Susan E Burwig, and Tom C King.
View insider buying and selling activity for Medpace or view top insider-selling stocks.

Which institutional investors are buying Medpace stock?

MEDP stock was acquired by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Russell Investments Group Ltd., Mountain Capital Investment Advisors Inc, Forte Capital LLC ADV, Retirement Systems of Alabama, Lindbrook Capital LLC, Future Financial Wealth Managment LLC, and YorkBridge Wealth Partners LLC. Company insiders that have bought Medpace stock in the last two years include Peter J O'malley, and Wedbush Securities Inc.
View insider buying and selling activity for Medpace or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $164.78.

How much money does Medpace make?

Medpace has a market capitalization of $5.92 billion and generates $925.92 million in revenue each year. The company earns $145.38 million in net income (profit) each year or $4.84 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 3,600 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

Where are Medpace's headquarters?

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at (513) 579-9911, via email at [email protected], or via fax at 513-579-0444.